Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial Read more about Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI) Read more about Role of circulating tumor DNA (ctDNA) from Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation (LIBERTI)
Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease Read more about Analytical development of the RaDaRTM assay, a highly sensitive and specific assay for the monitoring of minimal residual disease
Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer Read more about Residual ctDNA after treatment predicts early relapse in patients with early stage non-small cell lung cancer
Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay Read more about Predicting pathological response after ipilimumab plus nivolumab in stage III urothelial cancer by liquid-biopsy assessment of plasma and urine ctDNA using the RaDaR assay
Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma Read more about Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma
Evaluation of a tumor informed MRD assay with contrived breast cancer samples Read more about Evaluation of a tumor informed MRD assay with contrived breast cancer samples
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer Read more about Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Read more about Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD) Read more about A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)